Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVR1 | Q04771 | 5/20 | 0.41 |
| ▸ | MTOR | P42345 | 5/20 | 0.40 |
| ▸ | MLST8 | Q9BVC4 | 3/20 | 0.40 |
| ▸ | RICTOR | Q6R327 | 2/20 | 0.40 |
| ▸ | MAPKAP1 | Q9BPZ7 | 2/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.39 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 3/20 | 0.37 |
| ▸ | JAK3 | P52333 | 2/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | TYK2 | P29597 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.37 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | PAK4 | O96013 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2956126 | 0.84 | PIK3CA (0.39) | ACVR1MTORMLST8FAAHPIK3CA | |
| SCHEMBL13941212 | 0.82 | ACVR1 (0.44) | ACVR1MTORMLST8RICTORMAPKAP1 | |
| SCHEMBL2957264 | 0.82 | BRAF (0.48) | ACVR1MTORMLST8RICTORMAPKAP1 | |
| SCHEMBL2639880 | 0.80 | ACVR1 (0.42) | ACVR1MTORMLST8RICTORMAPKAP1 | |
| SCHEMBL2965356 | 0.78 | ACVR1 (0.38) | ACVR1JAK2JAK3JAK1TYK2 | |
| SCHEMBL2640038 | 0.71 | BRAF (0.46) | ACVR1MTORFAAHPIK3CAPIK3CD | |
| SCHEMBL2639907 | 0.69 | BRAF (0.46) | ACVR1MAP3K12 | |
| SCHEMBL13217501 | 0.69 | BRAF (0.46) | ACVR1JAK1MAP3K12 | |
| SCHEMBL2966602 | 0.68 | ACVR1 (0.38) | ACVR1JAK2JAK3JAK1TYK2 | |
| SCHEMBL20354363 | 0.67 | ACVR1 (0.56) | ACVR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772246-B2 | Pyrazole compounds as RAF inhibitors | PFIZER INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772246-B2 | Pyrazole compounds as RAF inhibitors | PFIZER INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772246-B2 | Pyrazole compounds as RAF inhibitors | PFIZER INC. (US) | 2010-08-10 | — | — | US | disclosed |
| EP-2183243-A2 | PYRAZOLE COMPOUNDS AND THEIR USE AS RAF INHIBITORS | Pfizer Inc. (US) | 2010-05-12 | — | — | EP | disclosed |
| US-20090221608-A1 | PYRAZOLE COMPOUNDS | PFIZER INC. | 2009-09-03 | — | — | US | disclosed |
| US-20090221608-A1 | PYRAZOLE COMPOUNDS | PFIZER INC. | 2009-09-03 | — | — | US | disclosed |
| US-20090221608-A1 | PYRAZOLE COMPOUNDS | PFIZER INC. | 2009-09-03 | — | — | US | disclosed |
| WO-2009016460-A2 | PYRAZOLE COMPOUNDS AND THEIR USE AS RAF INHIBITORS | PFIZER INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009016460-A2 | PYRAZOLE COMPOUNDS AND THEIR USE AS RAF INHIBITORS | PFIZER INC. (US) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221608-A1 | PYRAZOLE COMPOUNDS | BRAF, RAF1, NRAS | ACVR1 4191/4885MTOR 104/4885MLST8 1101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.